These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 32612613)

  • 1. Activation of TLR7 and Innate Immunity as an Efficient Method Against COVID-19 Pandemic: Imiquimod as a Potential Therapy.
    Poulas K; Farsalinos K; Zanidis C
    Front Immunol; 2020; 11():1373. PubMed ID: 32612613
    [No Abstract]   [Full Text] [Related]  

  • 2. Could imiquimod (Aldara 5% cream) or other TLR7 agonists be used in the treatment of COVID-19?
    Avcilar H; Eken A
    Med Hypotheses; 2020 Nov; 144():110202. PubMed ID: 33254510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19.
    Angelopoulou A; Alexandris N; Konstantinou E; Mesiakaris K; Zanidis C; Farsalinos K; Poulas K
    Environ Res; 2020 Sep; 188():109858. PubMed ID: 32846644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Systems Biology Workflow for Drug and Vaccine Repurposing: Identifying Small-Molecule BCG Mimics to Reduce or Prevent COVID-19 Mortality.
    Hajjo R; Tropsha A
    Pharm Res; 2020 Oct; 37(11):212. PubMed ID: 33025261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Comprehensive Updated Review on SARS-CoV-2 and COVID-19.
    Ren YR; Golding A; Sorbello A; Ji P; Chen J; Saluja B; Witzmann K; Arya V; Reynolds KS; Choi SY; Nikolov NP; Sahajwalla C
    J Clin Pharmacol; 2020 Aug; 60(8):954-975. PubMed ID: 32469437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19: Small-Molecule Clinical Trials Landscape.
    Ferreira LLG; Andricopulo AD
    Curr Top Med Chem; 2020; 20(18):1577-1580. PubMed ID: 32862824
    [No Abstract]   [Full Text] [Related]  

  • 7. Surviving COVID-19: A disease tolerance perspective.
    Ayres JS
    Sci Adv; 2020 May; 6(18):eabc1518. PubMed ID: 32494691
    [No Abstract]   [Full Text] [Related]  

  • 8. SARS-CoV-2: a time for clear and immediate action.
    Poland GA
    Lancet Infect Dis; 2020 May; 20(5):531-532. PubMed ID: 32243818
    [No Abstract]   [Full Text] [Related]  

  • 9. Prevention and treatment of COVID-19 disease by controlled modulation of innate immunity.
    Schijns V; Lavelle EC
    Eur J Immunol; 2020 Jul; 50(7):932-938. PubMed ID: 32438473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emergence of novel coronavirus and progress toward treatment and vaccine.
    Khan MM; Noor A; Madni A; Shafiq M
    Rev Med Virol; 2020 Jul; 30(4):e2116. PubMed ID: 32495979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Importance of Cellular Immunity in the Development of Vaccines and Therapeutics for COVID-19.
    Schlom J; Donahue RN
    J Infect Dis; 2020 Oct; 222(9):1435-1438. PubMed ID: 32651586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statin therapy and SAR-COV-2: an available and potential therapy?
    Abdel-Latif RG; Mohammed S; Elgendy IY
    Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):333-334. PubMed ID: 32379307
    [No Abstract]   [Full Text] [Related]  

  • 13. More questions than answers, and a way ahead.
    La Manna G
    G Ital Nefrol; 2020 Apr; 37(2):. PubMed ID: 32281753
    [No Abstract]   [Full Text] [Related]  

  • 14. Potential Unconventional Medicines for the Treatment of SARS-CoV-2.
    Coppola M; Mondola R
    Drug Res (Stuttg); 2020 Jun; 70(6):286. PubMed ID: 32428941
    [No Abstract]   [Full Text] [Related]  

  • 15. Covid-19 management with inflammation resolving mediators? Perspectives and potential.
    Regidor PA
    Med Hypotheses; 2020 Sep; 142():109813. PubMed ID: 32416413
    [No Abstract]   [Full Text] [Related]  

  • 16. Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19.
    Omarjee L; Janin A; Perrot F; Laviolle B; Meilhac O; Mahe G
    Clin Immunol; 2020 Jul; 216():108464. PubMed ID: 32405269
    [No Abstract]   [Full Text] [Related]  

  • 17. Immunomodulation in COVID-19.
    Ingraham NE; Lotfi-Emran S; Thielen BK; Techar K; Morris RS; Holtan SG; Dudley RA; Tignanelli CJ
    Lancet Respir Med; 2020 Jun; 8(6):544-546. PubMed ID: 32380023
    [No Abstract]   [Full Text] [Related]  

  • 18. Nutraceuticals have potential for boosting the type 1 interferon response to RNA viruses including influenza and coronavirus.
    McCarty MF; DiNicolantonio JJ
    Prog Cardiovasc Dis; 2020; 63(3):383-385. PubMed ID: 32061635
    [No Abstract]   [Full Text] [Related]  

  • 19. The race to make COVID antibody therapies cheaper and more potent.
    Ledford H
    Nature; 2020 Nov; 587(7832):18. PubMed ID: 33097846
    [No Abstract]   [Full Text] [Related]  

  • 20. Oxytocin as a potential defence against Covid-19?
    Soumier A; Sirigu A
    Med Hypotheses; 2020 Jul; 140():109785. PubMed ID: 32344303
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.